Science
A blood test that predicts GLP-1 response could help doctors pick the right patients. No data is available yet to judge how real or useful this test is.
Drug makers are racing past GLP-1 shots to triple-action obesity drugs. Patents show how companies plan to protect these next-wave products.
A study in The Lancet found that semaglutide (a weight-loss drug) reduced how much people with alcohol addiction drank and lowered their cravings for alcohol. The finding suggests the drug might help treat alcoholism, though more testing is needed.
Semaglutide may help people drink less. If it works, Novo's drug could be used for more than weight loss and diabetes.
Fujifilm built a new tool to find cyclic peptides that stick to hard-to-drug proteins. Early-stage platform work with no named drug or trial yet.
A new lab-stage drug worked better than current shots in mice. It is years away from people, but it shows drugmakers want stronger options than Ozempic.
Patients on GLP-1 drugs often ask if these shots affect fertility or pregnancy. Clear guidance helps doctors counsel women who want to get pregnant.
Scientists found reasons why some people don't lose weight when taking GLP-1 drugs like semaglutide. The research could help doctors predict who will respond to these medicines and who won't.
Some people don't lose weight on GLP-1 drugs. This research may help doctors pick the right patients before prescribing.
Peptide therapies are getting popular fast, but doctors warn the science isn't there yet. More buzz could bring more rules and warnings.
BPC-157 stays a gray-market peptide with no FDA approval. Doctor commentary in mainstream press shapes how patients view it but does not change the rules.
Researchers found a link between weight-loss drugs like semaglutide and changes in how much alcohol people drink. The study suggests these drugs may affect people's desire to use alcohol, similar to how they reduce appetite for food.
Weight-loss shots like Ozempic may also cut how much people drink. That could open a new use for these drugs to help with alcohol problems.
A blood test that predicts who responds to GLP-1 drugs could help doctors pick the right patients. But this is early-stage research with no clinical proof yet.
Semaglutide may help people with depression feel more motivated. If this holds up in bigger studies, it could open a new use for Novo's drug beyond weight loss and diabetes.
A study found that tirzepatide (a weight-loss and diabetes drug) was tied to fewer deaths and side effects than semaglutide (another similar drug). The comparison suggests tirzepatide may have a safety advantage over semaglutide.
A head-to-head safety edge for tirzepatide over semaglutide could push more doctors and patients toward Lilly's drug instead of Novo's.
A health news outlet explores whether GLP-1 drugs like semaglutide (Ozempic) might help people stop drinking alcohol. The article examines what research shows about using weight-loss medications to treat alcoholism.
Doctors are looking at GLP-1 drugs like Ozempic for new uses. If they help with drinking, demand could grow beyond weight loss and diabetes.
Semaglutide may help people drink less alcohol. If the data holds up, Novo could push for a new use, but the FDA has no clear path yet.
Semaglutide may help people drink less alcohol. That could open a new use for Novo's drug beyond diabetes and weight loss.
A study found that people taking semaglutide (Ozempic, Wegovy) who experienced constipation lost more weight than those who didn't. The finding suggests constipation may be tied to how well the drug works, though more research is needed to understand why.
People on Ozempic or Wegovy who get constipated may lose more weight. Doctors might use this as a clue that the drug is working.
A study shows semaglutide (a weight-loss and diabetes drug) costs less and works better than resmetirom for treating MASH, a serious liver disease. The findings may influence which drug doctors choose for patients.
Novo's semaglutide may take MASH market share from Madrigal's resmetirom if doctors pick the cheaper, better option for liver disease patients.
A study found that people taking semaglutide (Ozempic) for weight loss had lower rates of depression and anxiety. The finding suggests the drug may have mental health benefits beyond its main use for losing weight.
Ozempic may help mood, not just weight. That could give Novo a new selling point and push more doctors to prescribe it.
A study found a link between GLP-1 drugs (weight-loss medicines like semaglutide) and hair loss. The finding adds to safety concerns doctors and patients are watching as these drugs become more popular.
Hair loss could be added to the list of side effects people worry about with GLP-1 drugs like Ozempic. This may make some patients think twice before starting.
Tirzepatide may protect eyes in people with diabetes. That gives Lilly's drug another reason for doctors to pick it over older options.
A study found that Wegovy, Novo Nordisk's weight-loss shot, also helped people with alcohol addiction drink less. The finding suggests the drug may work on brain pathways linked to both weight and drinking habits.
Wegovy may help people drink less alcohol. That could open a new use for Novo's shot beyond weight loss, giving it a bigger market.
A new study found that GLP-1 drugs (like semaglutide) may help reduce heavy drinking in people. The research suggests these weight-loss medicines could have an unexpected benefit beyond weight control.
GLP-1 drugs may help heavy drinkers cut back. That could open a new use for Novo's semaglutide beyond weight loss and diabetes.
A study found that GLP-1 drugs (medications used for weight loss) reduced heavy drinking days in patients who had both obesity and alcohol use disorder. The research was published in the American Journal of Managed Care.
GLP-1 drugs may help people drink less if they have obesity and a drinking problem. This could grow the market for Novo and Lilly's weight-loss drugs.
A study found that semaglutide, the active ingredient in Ozempic and Wegovy, may help treat alcohol use disorder in people with obesity. The research is still early, but it suggests the drug might work for both weight loss and reducing alcohol use.
Semaglutide may help people with obesity drink less alcohol. If bigger studies confirm this, Novo's drug could be used for more than weight loss.
Early mouse data on a five-in-one obesity drug hints at where the next wave of weight-loss research is heading, but it is still far from human trials.
A new obesity drug idea hits five targets at once instead of just one or two. If it works, it could push past today's GLP-1 shots like Ozempic and Zepbound.
BPC-157 keeps getting media attention even though it has no FDA approval. Doctors and regulators worry about its growing off-label use.
Stopping and restarting GLP-1 drugs (like tirzepatide) for weight loss may make them work less well over time, according to research from Penn Medicine. The finding suggests people using these drugs should talk to their doctors before pausing treatment.
People who pause GLP-1 shots to save money may find the drugs work less well when they restart. That could push patients to stay on therapy longer.
Tirzepatide may help people who gain weight from other drugs they take. That gives Lilly's Zepbound a wider group of patients who could use it.